Nkarta, Inc.
NKTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $208.9M
$2.92
▲ +4.66%
P/E
-1.86
Mkt Cap
$208.9M
52-Wk Range
$1.70–$3.72
52-Week Range
$1.70 - $3.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- NK cell-based platform offers superior safety and manufacturing advantages over CAR-T therapies
- Strategic partnership with CRISPR Therapeutics enhances gene editing and cell engineering capabilities
- Proprietary chimeric antigen receptor technology targeting multiple cancer antigens
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase I clinical trial advancement of NKX101 for AML/MDS indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+21.7% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NKTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.54 vs -$0.36 consensus (-49.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-49.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 11, 2026
vs Industry
How NKTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related